Eurofins Selcia

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.  www.selcia.com 

 

  • 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)  
  • GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance  
  • Stable Labelling  (13C, 2H, 15N) Internal Standards, Metabolites and Impurities  
  • GLP Analysis Certification and Problem Solving including GLP NMR 

 

Radiolabelling to support Life Sciences: • Metabolism • Distribution • Mass Balance • Micro-dosing • Environmental fate • Dermal Penetration 

Company Type
Keywords
Twitter Account
@SelciaLtd

Evgen Pharma plc

Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. 

There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. 

Evgen exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.

Twitter Account
@EvgenPharma